|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Zantac
|
|
gptkbp:activities
|
inhibits gastric acid secretion
|
|
gptkbp:approves
|
gptkb:1983
|
|
gptkbp:brand
|
gptkb:Zantac
|
|
gptkbp:class
|
H2 receptor antagonist
|
|
gptkbp:clinical_trial
|
ranitidine efficacy study
ranitidine safety study
|
|
gptkbp:contraindication
|
allergy to ranitidine
|
|
gptkbp:current_use
|
gptkb:GERD
peptic ulcer disease
Zollinger-Ellison syndrome
|
|
gptkbp:dosage_form
|
gptkb:item
oral tablet
150 mg
|
|
gptkbp:effective_date
|
FDA approved
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
gptkbp:has_ability
|
75 mg
150 mg
300 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zantac 150
|
|
gptkbp:ingredients
|
gptkb:ranitidine
|
|
gptkbp:interacts_with
|
gptkb:itraconazole
gptkb:ketoconazole
gptkb:warfarin
|
|
gptkbp:is_atype_of
|
A02 B A02
|
|
gptkbp:is_used_for
|
treating heartburn
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:replaced_by
|
gptkb:2019
|
|
gptkbp:requires
|
over-the-counter
|
|
gptkbp:safety_features
|
may cause kidney problems
may cause liver problems
may cause stomach cancer
|
|
gptkbp:scholarships
|
do not exceed recommended dose
take before meals
consult doctor if symptoms persist
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
diarrhea
constipation
|
|
gptkbp:social_structure
|
C13 H12 N4 O3 S
|
|
gptkbp:storage
|
room temperature
|